Teriflunomide Accord

Country: European Union

Language: Croatian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

Teriflunomide

Available from:

Accord Healthcare S.L.U.

ATC code:

L04AA31

INN (International Name):

teriflunomide

Therapeutic group:

Imunosupresivima selektivni imunosupresivima

Therapeutic area:

Multipla Skleroza, Рецидивно-Ремиттирующее

Therapeutic indications:

Teriflunomide Accord is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (MS) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

Authorization status:

odobren

Authorization date:

2022-11-09

Patient Information leaflet

                                37
B. UPUTA O LIJEKU
38
UPUTA O LIJEKU: INFORMACIJE ZA BOLESNIKA _ _
TERIFLUNOMIDE ACCORD 7 MG FILMOM OBLOŽENE TABLETE
TERIFLUNOMIDE ACCORD 14 MG FILMOM OBLOŽENE TABLETE
teriflunomid
PAŽLJIVO PROČITAJTE CIJELU UPUTU PRIJE NEGO POČNETE UZIMATI OVAJ
LIJEK JER SADRŽI VAMA VAŽNE
PODATKE.
-
Sačuvajte ovu uputu. Možda ćete je trebati ponovno pročitati.
-
Ako imate dodatnih pitanja, obratite se liječniku ili ljekarniku.
-
Ovaj je lijek propisan samo Vama. Nemojte ga davati drugima. Može im
naškoditi, čak i ako su
njihovi znakovi bolesti jednaki Vašima.
-
Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti
liječnika ili ljekarnika. To uključuje
i svaku moguću nuspojavu koja nije navedena u ovoj uputi. Pogledajte
dio 4.
ŠTO SE NALAZI U OVOJ UPUTI:
1.
Što je Teriflunomide Accord i za što se koristi
2.
Što morate znati prije nego počnete uzimati Teriflunomide Accord
3.
Kako uzimati Teriflunomide Accord
4.
Moguće nuspojave
5.
Kako čuvati Teriflunomide Accord
6.
Sadržaj pakiranja i druge informacije
1.
ŠTO JE TERIFLUNOMIDE ACCORD I ZA ŠTO SE KORISTI
ŠTO JE TERIFLUNOMIDE ACCORD
Teriflunomide Accord sadrži djelatnu tvar teriflunomid koja je
imunomodulator i prilagođava
imunološki
sustav kako bi ograničio napad na živčani sustav.
ZA ŠTO SE TERIFLUNOMIDE ACCORD KORISTI
Teriflunomide Accord se koristi u odraslih osoba i u djece i
adolescenata (u dobi od 10 godina i
starijih) za liječenje relapsno-remitirajuće multiple skleroze (MS).
ŠTO JE MULTIPLA SKLEROZA
Multipla skleroza je dugotrajna bolest koja utječe na središnji
živčani sustav (SŽS). SŽS tvore mozak i
kralježnična moždina. U multiploj
sklerozi upala uništava zaštitnu ovojnicu (zvanu mijelin) oko
živaca
u SŽS-u. Taj gubitak mijelina naziva se demijelinizacijom
i onemogućuje pravilan rad živaca.
Osobe s relapsnim oblikom multiple skleroze imat će ponovljene
napadaje (relapse) tjelesnih
simptoma uzrokovane nepravilnim radom živaca. Ti se simptomi
razlikuju od bolesnika do bolesnika,
ali obično obuhvaćaju slj
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOG I.
SAŽETAK OPISA SVOJSTAVA LIJEKA
2
1.
NAZIV LIJEKA
Teriflunomide Accord 7 mg filmom obložene tablete
Teriflunomide Accord 14 mg filmom obložene tablete
2.
KVALITATIVNI I KVANTITATIVNI SASTAV
Teriflunomide Accord 7 mg filmom obložene tablete
Jedna filmom obložena tableta sadrži 7 mg teriflunomida.
_Pomoćna tvar s poznatim učinkom _
Jedna tableta sadrži 79 mg laktoza hidrata.
Teriflunomide Accord 14 mg filmom obložene tablete
Jedna filmom obložena tableta sadrži 14 mg teriflunomida.
_Pomoćna tvar s poznatim učinkom _
Jedna tableta sadrži 72 mg laktoza hidrata.
Za cjeloviti popis pomoćnih tvari, vidjeti dio 6.1.
3.
FARMACEUTSKI OBLIK
Filmom obložena tableta (tableta)
Teriflunomide Accord 7 mg filmom obložene tablete
Svijetlozeleno-plavkasto
siva do blijedozeleno-plava, šesterokutna, filmom obložena tableta
približnih
dimenzija 7,3 x 6,9 mm, s utisnutom oznakom „T1“ na jednoj strani
i bez oznake na drugoj strani.
Teriflunomide Accord 14 mg filmom obložene tablete
Plava, peterokutna, filmom obložena tableta približnih
dimenzija 7,3 × 7,2 mm, s utisnutom oznakom
„T2“ na jednoj strani i bez oznake na drugoj strani.
4.
KLINIČKI PODACI
4.1
TERAPIJSKE INDIKACIJE
Teriflunomide Accord je indiciran za liječenje odraslih bolesnika i
pedijatrijskih
bolesnika u dobi od
10 godina i starijih s relapsno-remitirajućom multiplom
sklerozom (MS) (vidjeti dio 5.1 za važne
informacije o populacijama u kojih je utvrđena djelotvornost lijeka).
4.2
DOZIRANJE I NAČIN PRIMJENE
Liječenje mora započeti i nadzirati liječnik s iskustvom u
liječenju multiple skleroze.
Doziranje
_Odrasli _
U odraslih, preporučena doza teriflunomida je 14 mg jedanput na dan.
3
_Pedijatrijska populacija (u dobi od 10 godina i stariji) _
U pedijatrijskih bolesnika (u dobi od 10 godina i starijih),
preporučena doza ovisi o tjelesnoj težini:
-
Pedijatrijski bolesnici s tjelesnom težinom >40 kg: 14 mg jedanput na
dan.
-
Pedijatrijski bolesnici s tjelesnom težinom ≤40 kg: 7 mg jedanput
na dan.
Pedijatrijski boles
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 25-04-2024
Summary of Product characteristics Summary of Product characteristics Bulgarian 25-04-2024
Public Assessment Report Public Assessment Report Bulgarian 21-09-2023
Patient Information leaflet Patient Information leaflet Spanish 25-04-2024
Public Assessment Report Public Assessment Report Spanish 21-09-2023
Patient Information leaflet Patient Information leaflet Czech 25-04-2024
Public Assessment Report Public Assessment Report Czech 21-09-2023
Patient Information leaflet Patient Information leaflet Danish 25-04-2024
Public Assessment Report Public Assessment Report Danish 21-09-2023
Patient Information leaflet Patient Information leaflet German 25-04-2024
Public Assessment Report Public Assessment Report German 21-09-2023
Patient Information leaflet Patient Information leaflet Estonian 25-04-2024
Public Assessment Report Public Assessment Report Estonian 21-09-2023
Patient Information leaflet Patient Information leaflet Greek 25-04-2024
Public Assessment Report Public Assessment Report Greek 21-09-2023
Patient Information leaflet Patient Information leaflet English 25-04-2024
Public Assessment Report Public Assessment Report English 21-09-2023
Patient Information leaflet Patient Information leaflet French 25-04-2024
Public Assessment Report Public Assessment Report French 21-09-2023
Patient Information leaflet Patient Information leaflet Italian 25-04-2024
Public Assessment Report Public Assessment Report Italian 21-09-2023
Patient Information leaflet Patient Information leaflet Latvian 25-04-2024
Public Assessment Report Public Assessment Report Latvian 21-09-2023
Patient Information leaflet Patient Information leaflet Lithuanian 25-04-2024
Summary of Product characteristics Summary of Product characteristics Lithuanian 25-04-2024
Public Assessment Report Public Assessment Report Lithuanian 21-09-2023
Patient Information leaflet Patient Information leaflet Hungarian 25-04-2024
Summary of Product characteristics Summary of Product characteristics Hungarian 25-04-2024
Public Assessment Report Public Assessment Report Hungarian 21-09-2023
Patient Information leaflet Patient Information leaflet Maltese 25-04-2024
Public Assessment Report Public Assessment Report Maltese 21-09-2023
Patient Information leaflet Patient Information leaflet Dutch 25-04-2024
Public Assessment Report Public Assessment Report Dutch 21-09-2023
Patient Information leaflet Patient Information leaflet Polish 25-04-2024
Public Assessment Report Public Assessment Report Polish 21-09-2023
Patient Information leaflet Patient Information leaflet Portuguese 25-04-2024
Summary of Product characteristics Summary of Product characteristics Portuguese 25-04-2024
Public Assessment Report Public Assessment Report Portuguese 21-09-2023
Patient Information leaflet Patient Information leaflet Romanian 25-04-2024
Public Assessment Report Public Assessment Report Romanian 21-09-2023
Patient Information leaflet Patient Information leaflet Slovak 25-04-2024
Public Assessment Report Public Assessment Report Slovak 21-09-2023
Patient Information leaflet Patient Information leaflet Slovenian 25-04-2024
Summary of Product characteristics Summary of Product characteristics Slovenian 25-04-2024
Public Assessment Report Public Assessment Report Slovenian 21-09-2023
Patient Information leaflet Patient Information leaflet Finnish 25-04-2024
Public Assessment Report Public Assessment Report Finnish 21-09-2023
Patient Information leaflet Patient Information leaflet Swedish 25-04-2024
Public Assessment Report Public Assessment Report Swedish 21-09-2023
Patient Information leaflet Patient Information leaflet Norwegian 25-04-2024
Summary of Product characteristics Summary of Product characteristics Norwegian 25-04-2024
Patient Information leaflet Patient Information leaflet Icelandic 25-04-2024
Summary of Product characteristics Summary of Product characteristics Icelandic 25-04-2024

Search alerts related to this product